Dr. Gajewski received his A.B. from Notre Dame and his M. D from Temple University in Philadelphia, Pennsylvania. He completed his post graduate medical training at University of Cincinnati and UCLA, and is Board Certified in Internal Medicine, Hematology, and Oncology. Dr. Gajewski is currently a Professor of Medicine at The University of Texas, M.D. Anderson Cancer Center located in Houston, Texas – which is celebrating six decades of making Cancer history, and is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention.

His major area of interest has been increasing the success of alternative donor transplants for patients who need an allogeneic marrow transplant but lacking a sibling donor. Early in his career, he focused exclusively on transplants involving unrelated donors. His work included utilizing the new molecular tissue typing techniques to predict transplant outcomes and cell processing techniques to reduce the risk of post-transplant graft-versus-host disease, the major cause of mortality of alternative donor marrow transplants. This cell processing work has allowed him to do research on using half-matched relatives (i.e., parents or children) as donors. Success here could make allogeneic bone marrow transplantation feasible for most patients lacking a sibling donor. This cell processing technology is also being developed by him and others to use bone marrow cells to treat heart failure.
in addition to this research, Dr. Gajewski has focused his administrative efforts on improving access to marrow transplant services for patients in need of marrow transplants to cure their malignancy or blood disorder. He has worked on the issues related to contracting for managed care services with both managed care payers and governmental payers. From this work, he become interested and developed expertise in cost analysis of marrow transplantation and cancer therapy in general. This has ultimately led him into national efforts to measure quality of outcomes for transplant programs. As a consequence of this administrative work , he has been asked by the National Marrow Donor Program, American Society of Hematology and other national organizations to work on committees and task forces addressing access issues, costs of health care implications and quality outcomes for both marrow transplantation, cancer care and health care in general.

Dr. Albert H. Owens, Jr.

Dr. Albert H. Owens, Jr. is the Founder, Chief Scientific Officer and Director of FASgen, Inc., a drug development company founded in 2000 by distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis.  Dr. Owens was President of the Johns Hopkins Hospital (1987-1989) and Founder of the Johns Hopkins University Oncology Center.  Dr. Owens has been recognized as a founding father of the discipline of oncology in the United States, and was honored by Johns Hopkins University in October, 2006, when the new auditorium facility at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins was named in his honor, recognizing his contribution to cancer research and to Johns Hopkins over the last 40 years.

Dr. Owens took his degrees at Johns Hopkins (B.S. in 1949, M.D. in 1949), interned at The Johns Hopkins Hospital (1949-50), and, following his residency at JHU Hospital (1952-53), has served as a professor at The Johns Hopkins University School of Medicine.  He has served as President of American Cancer Institutes, 1990-1991, and Chairman of its Board of Directors in 1991-1992.  He has also served as Chairman of the National Coalition for Cancer Research, 1990-1992; and as its President, 1996-1998.

Dr. Robert Stuart

Dr. Robert K. Stuart is one of the nation's leading cancer research scientists and a leading practioner in the field of oncology. After taking his B.S. from Georgetown University in 1970 and his M.D. from The Johns Hopkins School of Medicine in 1974 Dr. Stuart stayed at Johns Hopkins as an Intern, Assistant Resident, Fellow in Oncology, Fellow in Medicine, and Assistant Professor of Oncology and Medicine, leaving in 1986 to start the new Hematology/Oncology Center at the Medical University of South Carolina. A signal achievement was his role in starting a bone marrow transplant program at the medical center.
From 1997 through 2001 Dr. Stuart was Chairman of the Department of Oncology at the King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia. In 2001 he returned to the Medical University of South Carolina.

Dr. Stuart served on the Board of Directors of the Aplastic Anemia Foundation of America and as Secretary and Vice President from 1983 through 1993.

An avid bicycle rider Dr. Stuart has ridden across the country on the Bristol-Myers Squibb Tour of Hope, wearing a hospital ID bracelet with his wife's name on it to remind him of her recovery from leukemia.
A survivor of kidney cancer himself Dr. Stuart is a true humanitarian who has devoted his life to helping patients achieve medical miracles.